F Wendling

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi Thrombopoietin: its role from early hematopoiesis to platelet production
    F Wendling
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Haematologica 84:158-66. 1999
  2. ncbi Mpl ligand or thrombopoietin: biological activities
    F Wendling
    INSERM U362, Institut Gustave Roussy, Villejuif, France
    Biotherapy 10:269-77. 1998
  3. ncbi Thrombopoietin and its receptor
    F Wendling
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Eur Cytokine Netw 9:221-31. 1998
  4. ncbi c-mpl, the thrombopoietin receptor
    W Vainchenker
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Thromb Haemost 74:526-8. 1995
  5. ncbi High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin
    K Cohen-Solal
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Blood 93:2859-66. 1999
  6. ncbi Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis
    K Cohen-Solal
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Blood 88:2578-84. 1996
  7. ncbi Thrombopoietin (TPO) knockout phenotype induced by cross-reactive antibodies against TPO following injection of mice with recombinant adenovirus encoding human TPO
    M A Abina
    Institut National de la Sante et de la Recherche Medicale, Unité 362, Institut Gustave Roussy, Villejuif, France
    J Immunol 160:4481-9. 1998
  8. ncbi Role of p21(Cip1/Waf1) in cell-cycle exit of endomitotic megakaryocytes
    V Baccini
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Blood 98:3274-82. 2001
  9. ncbi cMpl ligand is a humoral regulator of megakaryocytopoiesis
    F Wendling
    INSERM U362, Institut Gustave Roussy, Villejuif, France
    Nature 369:571-4. 1994
  10. ncbi Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette
    A Dugray
    INSERM U362, Institut Gustave Roussy, Villejuif, France
    Leukemia 15:1658-62. 2001

Collaborators

Detail Information

Publications12

  1. ncbi Thrombopoietin: its role from early hematopoiesis to platelet production
    F Wendling
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Haematologica 84:158-66. 1999
    ..The review also highlights the results so far obtained in preclinical and clinical trials...
  2. ncbi Mpl ligand or thrombopoietin: biological activities
    F Wendling
    INSERM U362, Institut Gustave Roussy, Villejuif, France
    Biotherapy 10:269-77. 1998
    ..In the near future, it is likely that new insights will be obtained in the physiopathological mechanisms underlying abnormal platelet production in human...
  3. ncbi Thrombopoietin and its receptor
    F Wendling
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Eur Cytokine Netw 9:221-31. 1998
    ..Preclinical and clinical studies demonstrate the potential use of TPO in a variety of contexts, but it is too early to evaluate its benefit in reducing platelet transfusion...
  4. ncbi c-mpl, the thrombopoietin receptor
    W Vainchenker
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Thromb Haemost 74:526-8. 1995
    ..This molecule (Mpl ligand/TPO/MK-CSF) seems to be the humoral physiological regulator of platelet production...
  5. ncbi High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin
    K Cohen-Solal
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Blood 93:2859-66. 1999
    ..These results show that TPO does not have a major effect on the transcription or translation of Mpl. However, they do suggest that an excess of circulating TPO can lead to the disappearance of Mpl from PLTs via catabolism...
  6. ncbi Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis
    K Cohen-Solal
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Blood 88:2578-84. 1996
    ..Together, these different models extend and further confirm that the regulation of Mpl-L does not occur at a transcriptional level or by a modulation in the ratios of Mpl-L mRNA isoforms...
  7. ncbi Thrombopoietin (TPO) knockout phenotype induced by cross-reactive antibodies against TPO following injection of mice with recombinant adenovirus encoding human TPO
    M A Abina
    Institut National de la Sante et de la Recherche Medicale, Unité 362, Institut Gustave Roussy, Villejuif, France
    J Immunol 160:4481-9. 1998
    ..Finally, we hypothesize that in humans some chronic thrombocytopenia associated with a low TPO plasma level are due to anti-TPO Abs...
  8. ncbi Role of p21(Cip1/Waf1) in cell-cycle exit of endomitotic megakaryocytes
    V Baccini
    INSERM U 362, Institut Gustave Roussy, Villejuif, France
    Blood 98:3274-82. 2001
    ..However, high levels of its expression in cultured megakaryocytes arrest the endomitotic cell cycle...
  9. ncbi cMpl ligand is a humoral regulator of megakaryocytopoiesis
    F Wendling
    INSERM U362, Institut Gustave Roussy, Villejuif, France
    Nature 369:571-4. 1994
    ..Our results suggest that c-Mpl ligand, thrombopoietin and MK-CSF might be the same molecule...
  10. ncbi Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette
    A Dugray
    INSERM U362, Institut Gustave Roussy, Villejuif, France
    Leukemia 15:1658-62. 2001
    ..Our data suggest that with further improvements of the retrovirus-mediated gene transfer technology, it might be possible to generate inducible leukemia models in mice by the use of single retroviral constructs...
  11. ncbi Adenoviral supply of active transforming growth factor-beta1 (TGF-beta1) did not prevent lethality in transforming growth factor-beta1-knockout embryos
    H Chagraoui
    INSERM U 362, Institut Gustave Roussy, PR1, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Eur Cytokine Netw 12:561-7. 2001
    ..These results indicate that transplacental passage of TGF-beta1 was not effective in rescuing TGF-beta1-null conceptuses from embryonic lethality...
  12. ncbi Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts
    E L Scolan
    Inserm U528, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Oncogene 20:5484-92. 2001
    ..Moreover Epo independence and tumorigenicity appear as separable phenotypic characteristics revealing that the spi-1-Tg proerythroblasts progress towards malignancy through multiple oncogenic events...